We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+8.24%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.42B
AUM Growth
+$102M
Cap. Flow
+$35.6M
Cap. Flow %
2.51%
Top 10 Hldgs %
72.95%
Holding
34
New
3
Increased
10
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$20.5M
2
APGE icon
Apogee Therapeutics
APGE
+$17.1M
3
CRM icon
Salesforce
CRM
+$15.3M
4
VALN
Valneva
VALN
+$15.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$22.4M
2
VERV
Verve Therapeutics
VERV
+$13.7M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$7.34M
4
LXEO icon
Lexeo Therapeutics
LXEO
+$3.9M
5
KYTX icon
Kyverna Therapeutics
KYTX
+$3.57M

Sector Composition

Rank Sector Weight
1 Healthcare 48.34%
2 Technology 15.92%
3 Financials 10.18%
4 Consumer Discretionary 2.98%
5 Industrials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$656B
$316M 22.28%
1,038,550
– –
BN icon
2
Brookfield
BN
$104B
$144M 10.18%
3,496,245
– –
ASML icon
3
ASML
ASML
$608B
$133M 9.38%
165,836
– –
CRM icon
4
Salesforce
CRM
$149B
$90M 6.36%
330,187
+57,386
+21% +$15.3M
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.84B
$76.3M 5.39%
1,500,055
+55
+0% +$2.45K
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.34B
$70.1M 4.95%
5,350,000
– –
INSM icon
7
Insmed
INSM
$22.6B
$68.4M 4.83%
680,000
-44,666
-6% -$3.42M
RXRX icon
8
Recursion Pharmaceuticals
RXRX
$1.62B
$48.9M 3.45%
9,665,128
– –
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$44.6M 3.15%
1,550,000
+275,000
+22% +$8.49M
BABA icon
10
Alibaba
BABA
$276B
$42.2M 2.98%
372,327
– –
AVBP icon
11
ArriVent BioPharma
AVBP
$1.4B
$40.8M 2.88%
1,872,142
– –
MRUS
12
DELISTED
Merus
MRUS
$39.5M 2.78%
750,000
-39,129
-5% -$1.84M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$12B
$36.3M 2.56%
660,000
+170,000
+35% +$10M
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$34M 2.4%
264,956
+36,152
+16% +$3.75M
VRDN icon
15
Viridian Therapeutics
VRDN
$2.15B
$33.3M 2.35%
2,380,000
+129,700
+6% +$1.76M
PHVS icon
16
Pharvaris
PHVS
$2.35B
$30.4M 2.14%
1,725,000
– –
PCVX icon
17
Vaxcyte
PCVX
$7.88B
$29.8M 2.1%
916,160
+1,160
+0.1% +$38K
CLDX icon
18
Celldex Therapeutics
CLDX
$2.79B
$24.4M 1.72%
1,200,000
– –
ZBIO
19
Zenas BioPharma
ZBIO
$2.04B
$21.8M 1.54%
2,250,000
+35,033
+2% +$341K
ELVN icon
20
Enliven Therapeutics
ELVN
$3.84B
$21.8M 1.54%
+1,084,432
New +$20.5M
APGE icon
21
Apogee Therapeutics
APGE
$10.1B
$19.5M 1.38%
+449,392
New +$17.1M
CBLL
22
CeriBell Inc
CBLL
$677M
$16.9M 1.19%
900,000
+20,000
+2% +$340K
VALN
23
Valneva
VALN
$517M
$13.5M 0.95%
+2,375,000
New +$15.1M
FDMT icon
24
4D Molecular Therapeutics
FDMT
$515M
$7.42M 0.52%
2,000,000
+50,000
+3% +$176K
IOBT
25
DELISTED
IO Biotech
IOBT
$4.66M 0.33%
3,354,449
– –
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q2 2025 Portfolio in Review

As of Q2 2025, Novo Holdings A/S held 34 positions worth $1.42B, up 7.8% from $1.31B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Novo Holdings A/S's Q2 2025 filing shows 3 new, 10 increased, 3 reduced and 5 closed positions. Its largest new stake was Enliven Therapeutics: 1,084,432 shares worth $21.8M. The largest sale was Amicus Therapeutics, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 51% a quarter earlier, followed by Technology and Financials.

  • Novo Holdings A/S's largest Q2 2025 buy was Enliven Therapeutics: 1,084,432 shares worth $21.8M.
  • Novo Holdings A/S added most to Salesforce in Q2 2025, an estimated $15.3M increase.
  • Novo Holdings A/S's biggest Q2 2025 reduction was Insmed, cutting an estimated $3.42M.
  • Novo Holdings A/S fully exited Amicus Therapeutics in Q2 2025, selling an estimated $22.4M.
  • Novo Holdings A/S's ten largest holdings make up 73% of its $1.42B portfolio in Q2 2025.
  • Novo Holdings A/S opened 3 new positions and closed 5 in Q2 2025.
  • Novo Holdings A/S's portfolio value rose 7.8% quarter-over-quarter to $1.42B.

Based on Novo Holdings A/S's 13F filing for Q2 2025, filed 14 Aug 2025.